ClinicalTrials.gg
Active, not recruitingNCT06812988T1D OBTAINUpdated Mar 13, 2026

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

A Phase 2 interventional study of Brivekimig and Placebo in Type 1 Diabetes Mellitus, sponsored by Sanofi. Active, not recruiting at 24 sites in 8 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Planned enrollment
31st of 60
84 · median 86
Started
2025
with 5 others
Phase 2
5 of 67
none open now
Registered
62nd of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 31st largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 5 in phase 2, and was the 62nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study.

The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy.

The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo).

The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.

Read the detailed description

The total study duration will be up to 83 weeks including Screening and Safety follow-up period.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 to 35 y.o. inclusive, at the time of signing the in order to be enrolled in Part A. Participant must be 12 to 21 y.o. inclusive, at the time of signing the informed consent in order to be enrolled in Part B.
  2. Participants who meet the criteria of T1D according to American Diabetes Association (ADA 2024).
  3. Initiated exogenous insulin replacement therapy not longer than 90 days prior to Screening visit at which random C-peptide will be assessed.
  4. Receiving insulin hormone replacement therapy:
  5. Participants must be positive for at least 1 of the following T1D autoantibodies confirmed by medical history and/or obtained at study Screening:

    • Glutamic acid decarboxylase (GAD-65)
    • Insulinoma Antigen-2 (IA-2)
    • Zinc-transporter 8 (ZnT8) or
    • Insulin (if obtained not later than 10 days after exogenous insulin therapy initiation)
  6. Have random C-peptide levels ≥0.2 nmol/L determined at Screening.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Serious systemic viral, bacterial or fungal infection (eg, pneumonia, pyelonephritis), infection requiring hospitalization or intravenous (IV) antibiotics or significant chronic viral (including history of recurrent or active herpes zoster, acute or active cytomegalovirus [CMV], Epstein-Barr Virus [EBV] as determined at Screening), bacterial, or fungal infection (eg, osteomyelitis) 30 days before and during Screening.
  2. History of invasive opportunistic infections, such as, but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, and aspergillosis, regardless of resolution.
  3. Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing.
  4. Evidence of any , severe or unstable, acute or, chronically progressive, uncontrolled infection, medical or surgical condition (eg, but not limited to, cerebral, cardiac, pulmonary, renal, hepatic, gastrointestinal, neurologic, or any known immune deficiency), or any condition that may affect participant safety in the judgment of the Investigator (including vaccinations which are not updated based on local regulation).
  5. History of a systemic reaction or significant allergies, other than localized injection site reaction, to any humanized mAb. Clinically significant multiple or severe drug allergies, intolerance to topical , or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  6. History of moderate to severe congestive heart failure (New York Health Association [] Class III or IV), or recent cerebrovascular accident, or any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol.
  7. History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.
  8. Has other or inflammatory conditions
  9. Diabetes of forms other than autoimmune T1D that include but are not limited to genetic forms of diabetes, maturity-onset diabetes of the young (MODY), latent autoimmune diabetes of the adult (LADA), secondary to medications or surgery, type 2 diabetes by judgment of the investigator.
  10. History of or lymphoproliferative disease other than adequately treated localized carcinoma in situ of the cervix or nonmetastatic squamous cell carcinoma, or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured or any family history in two or more relatives (immediate family) of same cancer (ie, rare cancers, those manifesting at a young age in a parent or sibling, certain genetic-based inheritable cancers).
  11. Systemic corticosteroids (duration >7 days), adrenocorticotropic hormone 1 month prior to Screening.
  12. Any IV, intramuscular (IM) or SC administered biologic treatments (mono- or polyclonal antibodies affecting function of immune system), \<3 months or \<5 half-lives (whichever is longer), prior to randomization.
  13. Any live (attenuated or viral-vector) vaccine (including but not limited to varicella zoster, oral polio, nasal influenza, rabies) within 3 months prior to randomization or is scheduled in expected period of study (78 weeks after randomization) if this vaccination cannot be safely postponed.
  14. Any non-live (inactivated, mRNA, recombinant, conjugate, toxoid) vaccine administered less than 14 days prior to randomization.
  15. Any therapy within 12 weeks prior to randomization and through 78 weeks after randomization
  16. Course of Thymoglobulin®, teplizumab or other immunomodulatory treatments at any time
  17. Any drugs that may be used for treatment of T1D and type 2 diabetes other than insulin including but not limited to metformin, glucagon-like peptide 1 (GLP-1) agonists, sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor, and verapamil within 2 weeks prior to Screening.
  18. Abnormal laboratory test(s) at Screening
  19. Participants who have impaired renal function with estimated (eGFR) (using the Modification of Diet in Renal Disease [MDRD] formula) \<60 mL/min/1.73 m2, or using the bedside Schwartz equation in the participants under the age of 18 y.o.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Brivekimig

    Participants will receive subcutaneous injection of brivekimig.

    Drug: Brivekimig

  • Placebo comparator
    Placebo

    Participants will receive subcutaneous injection of matching placebo.

    Drug: Placebo

Interventions

  • Pharmaceutical form: Solution Route of administration: Subcutaneous injection

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentration

    Mixed meal tolerance test MMTT stimulated C-peptide concentration is to be calculated from area under the concentration-time curve (AUC)

    Time frame: From Baseline to Week 26

Secondary outcomes

  1. Change from baseline to Week 52 in mean 2-hour MMTT stimulated Cpeptide concentration

    MMTT stimulated C-peptide concentration is to be calculated from area under the concentration-time curve (AUC)

    Time frame: From Baseline to Week 52

  2. Participant remaining C-peptide positive at Week 26 and Week 52

    Incidence (yes/no) outcome Defined as mean 2-hour MMTT stimulated C-peptide concentration ≥0.2 nmol/L

    Time frame: Week 26 and Week 52

  3. Time in range (TIR) (70-180 mg/dL) at Week 26 and Week 52

    Assessed by Continuous glucose monitoring (CGM). A CGM system is a device that records interstitial glucose levels continuously throughout the day and night via a subcutaneous sensor.

    Time frame: Week 26 and Week 52

  4. Change from baseline to Week 26 and Week 52 in insulin dose

    Expressed in IU/kg/day

    Time frame: From Baseline to Week 26 and Week 52

  5. Change from baseline to Week 26 and Week 52 in glycated hemoglobin A1c (HbA1c) level

    Time frame: From Baseline to Week 26 and Week 52

  6. Participant having HbA1c ≤6.5% and ≤0.25 IU/kg/day of exogenous insulin required at Week 26 and Week 52

    Incidence (yes/no) outcome

    Time frame: Week 26 and Week 52

  7. Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and TEAEs leading to treatment discontinuation

    Time frame: Up to End of Study (approx. 83 Weeks)

  8. Incidence (yes/no) of hypoglycemic events (level 2 or 3 according to American Diabetes Association)

    Incidence (yes/no) outcome

    Time frame: Up to End of Study (approx. 83 Weeks)

  9. Incidence (yes/no) of hyperglycemic episodes (level 2 according to American Diabetes Association)

    Incidence (yes/no) outcome

    Time frame: Up to End of Study (approx. 83 Weeks)

  10. Incidence (yes/no) of diabetic ketoacidosis (DKA) events

    Incidence (yes/no) outcome

    Time frame: Up to End of Study (approx. 83 Weeks)

  11. Incidence (yes/no) of clinically significant changes in vital signs, electrocardiogram (ECG), and/or laboratory evaluation

    Incidence (yes/no) outcome

    Time frame: Up to End of Study (approx. 83 Weeks)

  12. Brivekimig serum concentrations over time

    Time frame: Up to End of Study (approx. 83 Weeks)

  13. Incidence of anti-drug antibodies (ADAs) over time

    Time frame: Up to End of Study (approx. 83 Weeks)

  14. Change from baseline to Week 26 and Week 52 in Problem Areas in Diabetes (PAID) total score (all participants)

    The Problem Areas in Diabetes (PAID) is a diabetes specific instrument measuring diabetes distress. There is an adult version (18+) and a pediatric version for children 8-17 years of age. The PAID contains 20 items that describe negative emotions related to diabetes (eg, depression, anger, frustration). Item scores are summed to generate a total score. Scores range from 0 to 100, where higher total scores correspond to higher emotional distress due to diabetes

    Time frame: From Baseline to Week 26 and Week 52

  15. Change from baseline to Week 26 and Week 52 in PAID immediate and theoretical domain scores (caregivers of all participants 12 to 17 y.o.)

    Caregiver version of PAID for parents with children 8-18 years of age consists of 18 items that measure caregiver burden. Two scores are calculated: Immediate Burden and Theoretical Burden. Scores range from 0 to 100, where higher scores correspond to greater caregiver burden.

    Time frame: From Baseline to Week 26 and Week 52

07

Study locations

24 sites
  • Atlanta Diabetes Associates- Site Number : 8400006
    Atlanta, Georgia 30318, United States
  • IACT Health - Columbus - Talbotton Road- Site Number : 8400012
    Columbus, Georgia 31904, United States
  • Profound Research - MHP - TriAtria- Site Number : 8400015
    Farmington Hills, Michigan 48334, United States
  • Tekton Research - McKinney- Site Number : 8400017
    McKinney, Texas 75069, United States
  • Advanced Research Institute - Odgen- Site Number : 8400007
    Ogden, Utah 84405, United States
  • Investigational Site Number : 0320001
    Buenos Aires, 1119, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1178, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1180, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1419, Argentina
  • Investigational Site Number : 0320003
    Salta, 4400, Argentina
  • Investigational Site Number : 0360003
    Saint Leonards, New South Wales 2065, Australia
  • Investigational Site Number : 0360002
    Brisbane, Queensland 4029, Australia
  • Investigational Site Number : 0360001
    Parkville, Victoria 3050, Australia
  • Centro de Diabetes Curitiba- Site Number : 0760005
    Curitiba, Paraná 80810-040, Brazil
  • Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760002
    São Paulo, 01228-200, Brazil
  • Investigational Site Number : 1240006
    Surrey, British Columbia V3T 2V6, Canada
  • Investigational Site Number : 1240001
    Vancouver, British Columbia V5Y 3W2, Canada
  • Investigational Site Number : 1520004
    Concepción, Biobio 4070566, Chile
  • Investigational Site Number : 1520003
    Providencia, Reg Metropolitana de Santiago 7500000, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7500505, Chile
  • Investigational Site Number : 3760001
    Jerusalem, 9112001, Israel
  • Investigational Site Number : 3760003
    Kefar Sava, 4428164, Israel
  • Investigational Site Number : 3760002
    Ramat Gan, 5262100, Israel
  • Investigational Site Number : 6820002
    Riyadh, 12713, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Apr 2027, 26 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 26 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 6, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Apr 29, 2027
CompletionEst.
Apr 29, 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06812988
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Feb 28, 2025
Primary completion
Apr 29, 2027 (estimated)
Completion
Apr 29, 2027 (estimated)
Last update
Mar 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivekimig

Start the discussion